Evaluation of serum matrix metalloproteinase 2-7-9, tissue matrix metalloproteinase inhibitor 1, vasculer endothelial growth fakctor , interleukin 6 and interleukin 8 levels on breast cancinoma.

Purpose: The raising incidence of breast cancer and development of treatment modalities cause prolongation of survival and new markers are needed for follow up. Serum matrix metalloproteinase 2, 7, 9 (MMP2, MMP7, MMP9), tissue matrix metalloproteinase inhibitor 1 (TIMP1), interleukin 6, interleukin 8 and vasculer endotelial growth factor (VEGF) take different parts on cancerogenesis. The aim of study is to evaluate the relationship between these markers and clinical stage, histopathologic features and laboratuary parameters. Materials and methods: Seventyeight pathologically proven, chemotherapy naive breast cancer patients were enrolled. The analyses were carried out using SPSS v15 and p<0.05 was accepted as significant. Descriptive studies were analyzed using chi-square test and Mann-Whitney U-test depending on group numbers. Results: The median age of patients were 52±11.6. Patients were divided to non-metastatic and metastatic pattern. VEGF values were 3.4 fold higher in metastatic group. Raising of CA15-3 levels were statistically correlated with MMP9 and IL6. The elevation of LDH were associated with raised VEGF and TIMP1. CRP elevation was correlated with increased IL8, IL6 and MMP9. Raising of VEGF was associated with progression. VEGF levels of patients lost in follow up were higher although there was no statistically significance. MMP7 levels were lower in hormon positive group than negative group. MMP2 levels were higher in HER2 (3+) group than HER2 (0/1+/2+) patient group. TIMP1 levels were lower in patients whom ki 67 ratios were above 40% than below 40%. Conclusion: This is a preliminary study with low patient number and short follow up time